中国医药导报2013年lO月第lO卷第28期药物与临床缬沙坦氢氯噻嗪分散片和美托洛尔缓释片联用对高血压左室舒张功能减退的疗效观察胡智华广东省惠州市惠阳区人民医院广东省惠州市第六人民医院内科，广东惠州51621l【摘要】目的观察缬沙坦氢氯噻嗪分散片联合美托洛尔缓释片对高血压合并左室舒张功能减退的临床疗效。方法将惠州市惠阳区人民医院2011年5月一2012年5月收治的高血压合并左室舒张功能减退患者110例随机分为两组，每组各55例．对照组单用缬沙坦氢氯噻嗪分散片，观察组在此基础上联合美托洛尔缓释片。比较两组患者临床治疗效果。结果观察组总有效率为92．73％，明显高于对照组的78．18％，差异有统计学意义(x2=5．564，P=0．038)；两组治疗后血压、心率及心室舒张功能指标均有明显改变，且观察组收缩压(SBP)、舒张压(DBP)及心率(HR)分别为(120．45+10．89)mmHg、(77．45±8。44)mmHg和(70。39±5．53)次／min，均明显低于对照组(x2-4．544，P=0．035；x2=5．13，P=0．040；x2=6．05，P=0．027)；观察组治疗后左室舒张末期内径(LVEDd)和心室等容舒张时间(IVRT)分别为(47．65±4．01)mm和(101．26±4．87)ms，而E／A为(1．19±0．12)，与对照组比较差异均有统计学意义(x2．6．1l，P=0．025；x2-5．82，P=0．031；X2=5．56，P=0．039)。结论缬沙坦氢氯噻嗪分散片联合美托洛尔缓释片对高血压合并左室舒张功能减退效果显著，可有效控制患者血压．改善左室舒张功能，值得临床推广和应用。【关键词】缬沙坦氢氯噻嗪分散片；美托洛尔缓释片；左室舒张功能减退【中图分类号】1：1544．1【文献标识码】A【文章编号】1673—7210(2013)10(a)一0083—04Clinicalobservationofleftventriculardiastolicdysfunctioninpatients、订thhypertensiontreatedbyValsartanHydrochlorothiazideDispersibleTabletsandMetoprololSustained-releaseTablets日UZhihuaDepartmentofInternalMediciine，HuiyangDistrictPeople"sHospitalofHuizhouCityHuizhouSixthPeople’SHospital，GuangdongProvince，Huizhou516211，China[Abstract]ObjectiveToinvestigateclinicalefficacyofleftventrieulardiastolicdysfunctioninpatientswithhypertensiontreatedbyValsartanHydrochlorothiazideDispersibleTabletsandMetoprololSustained—releaseTablets．Methods110pa．tientsofhypertensionwithleftventriculardiastolicdysfunctionwererandomizedintotwogroups，whowereadmittedtoHuiyangDistrictPeople'sHospitalofHuizhouCityfromMay2011toMay2012werecollected．ThecontrolgroupwasonlytreatedbyValsartanHydrochlorothiazideconventionaldrugtreatment，andobservationgroupwasgivenMetoprololTabletsonthebasisofValsartanHydrochlorothiazide．Theclinicalefficacyforbothofthemwascompared．ResultsTheeffectiverateoftreatmentgroupwas92．73％，andtheeffectiverateofobservationgroupwassignificantlyhigherthanthecontrolgroup(78．18％)，therewasastatisticallysignificantdifferencebetweenthetwogroups(x2=5．564，P=0．038)．Aftertreatment，bloodpressure，heartrateandventriculardiastolicfunctionparametersweresignificantlychanged，astatisticallysignificantdiffer-encebetweenthetwogroupswasindicated(P<0．05)．Systolicbloodpressure(SBP)，diastolicbloodpressure(DBP)andheartrate(HR)ofobservationgroupwere(120．45±10．89)mmHg，(77．45±8．44)mmHgand(70．39±5．53)times／min，whichwerelowerthancontrolgroup(X2=4．544，P=0．035；x2=5．13，P=0．040；x2=6．05，P=0．027)；aftertreatment，leftventricularenddiastolicdiameter(LVEDd)andventrieularisovolumicrelaxationtime(1VRT)were(47．65±4．01)mmand(101．26±4．87)ms，whiletheE／Awas(1．19±0．12)，comparedwiththecontrolgroup，thedifferenceswerestatisticallysignificant(X2=6．11，P=0．025；X2=5．82，P=0．031；X2=5．56，P=0．039)．ConclusionValsartanHydroehlorothiazidecombinedwithMetoprol...
